Safety profile of once-weekly subcutaneous semaglutide in a real-world adult population with type 2 diabetes

被引：0
|
作者：
Yale, J. -F. [1 ]
Major-Pedersen, A. [2 ]
Catarig, A. -M. [3 ]
Jain, R. G. [4 ]
Menzen, M. [5 ]
Holmes, P. [6 ]
机构：
[1] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[2] Novo Nordisk AS, Global Safety, Soborg, Denmark
[3] Novo Nordisk AS, Soborg, Denmark
[4] Novo Nordisk Serv Ctr Private Ltd, Biostat, EPIP Area Whitefield, Mindcomp Tech Pk,2nd Phase, Bangalore, Karnataka, India
[5] Gemeinschaftskrankenhaus Bonn, Innere Med Diabetol, Bonn, Germany
[6] St Georges Med Practice, Yarm Rd, Darlington, Durham, England
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
670
引用
收藏
页码：S339 / S340
页数：2
相关论文
共 50 条
  • [31] Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
    Chioma Uzoigwe
    Yuanjie Liang
    Sarah Whitmire
    Yurek Paprocki
    Diabetes Therapy, 2021, 12 : 1475 - 1489
  • [32] Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
    Lee, Byung-Wan
    Cho, Young Min
    Kim, Sin Gon
    Ko, Seung-Hyun
    Lim, Soo
    Dahaoui, Amine
    Jeong, Jin Sook
    Lim, Hyo Jin
    Yu, Jae Myung
    DIABETES THERAPY, 2024, 15 (02) : 547 - 563
  • [33] Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study
    Ekberg, Neda Rajamand
    Bodholdt, Ulrik
    Catarig, Andrei-Mircea
    Catrina, Sergiu-Bogdan
    Grau, Katrine
    Holmberg, Cecilia Nagorny
    Klanger, Boris
    Knudsen, Soren Tang
    PRIMARY CARE DIABETES, 2021, 15 (05) : 871 - 878
  • [34] Real-World Effectiveness of Newly Initiated Once-Weekly Semaglutide (sema OW) by Prescriber Specialty
    Shivappa, Nitin
    Noone, Joshua
    Swift, Caroline
    Du, Simo
    Tan, Hiangkiat
    Paprocki, Yurek M.
    Willey, Vincent
    DIABETES, 2021, 70
  • [35] Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 mg Weekly Dose of Once-Weekly Semaglutide for Diabetes
    Gronroos, Noelle N.
    Swift, Caroline
    Frazer, Monica S.
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Alvarez, Sara
    Dunn, Tyler J.
    Noone, Josh
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2024, 11 (02): : 118 - 124
  • [36] Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
    Uzoigwe, Chioma
    Liang, Yuanjie
    Whitmire, Sarah
    Paprocki, Yurek
    DIABETES THERAPY, 2021, 12 (05) : 1475 - 1489
  • [37] Real-World Effectiveness of Once-Weekly Semaglutide (Sema OW) from a US Commercially Insured and Medicare Advantage Population
    Visaria, Jay
    Uzoigwe, Chioma
    Swift, Caroline
    Paprocki, Yurek M.
    Willey, Vincent
    DIABETES, 2020, 69
  • [38] Real-World Effectiveness of Once-Weekly Semaglutide (sema OW) from a US Commercially Insured and Medicare Advantage Population
    Willey, Vincent
    Shivappa, Nitin
    Noone, Joshua
    Swift, Caroline
    Du, Simo
    Yurek, M. Paprocki .
    Tan, Hiangkiat
    DIABETES, 2021, 70
  • [39] Predictors of Glycemic and Weight Response to Exenatide Once-Weekly in Patients with Type 2 Diabetes in a Real-World Setting
    Gorgojo-Martinez, Juan J.
    Brito-Sanfiel, Miguel A.
    Gargallo-Fernandez, Manuel A.
    Lisbona-Catalan, Arturo
    DIABETES, 2017, 66 : A297 - A297
  • [40] CEA OF ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE VERSUS DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES WITH INADEQUATE GLYCEMIC CONTROL IN CHINA
    Zhen, R.
    Ung, C. O. L.
    Shen, Y.
    Zou, H.
    Xue, Y.
    Wang, Y.
    Hu, H.
    VALUE IN HEALTH, 2022, 25 (07) : S368 - S368
12345